1. European Commission. Council conclusions on innovation for the benefit of patients (2014/C 438/06). Brussels: 6 December 2014.
2. Council of the European Union. Council conclusions on the “Reflection process on modern, responsive and sustainable health systems”. Employment, Social Policy, Health and Consumers Affairs. Council meeting. Brussels, 10 December 2013. 2013.
3. WHO Regional Office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen: 2015.
4. Ministry of Health Welfare and Sport. Summary of Medicines Plan. The Hague: 2016. Accessible at: http://english.eu2016.nl/binaries/eu2016-en/documents/publications/2016/03/1/summary-of-medicins/summary-of-medicines-plan.pdf . Accessed 14 May 2016.
5. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.